Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Figure 1 | Journal of Orthopaedic Surgery and Research

Figure 1

From: Targeting the osteosarcoma cancer stem cell

Figure 1

The impact of the osteosarcoma cancer stem cell model on future treatment design. (A) The response of osteosarcoma to chemotherapy alone: Chemotherapy shrinks the bulk of the tumor. However, chemoresistant CSCs may survive this therapy and then can self-renew and differentiate to reform the bulk of the tumor. CSCs therefore are responsible for osteosarcoma chemoresistance and tumor recurrence. (B) The proposed response of osteosarcoma to a combination of chemotherapy and CSC-targeted therapy: Combinational treatment will not only kill the majority of tumor cells but also the CSCs. The remaining non-CSC tumor cells will eventually exhaust their growth ability, resulting in complete eradication of the tumor.

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X